An advisory committee of Japan’s MHLW has given a favourable opinion for the approval of Eisai's Alzheimer's drug lecanemab, setting the stage for a possible full official approval in September, after which it would be co-commercialized with global partner Biogen.
An advisory committee to Japan’s Ministry of Health, Labour and Welfare (MHLW) has agreed on a positive approval recommendation for Eisai Co., Ltd./Biogen, Inc.’s Leqembi (lecanemab), for the treatment of early Alzheimer’s disease (AD).
Although the amyloid beta-targeting antibody - the first in its class in Japan - still requires a formal final official...
Torrent Pharma’s JB Chemicals acquisition follows the Curatio deal and Boehringer brands buyout. The second-biggest deal ever and the largest in 2025 among domestic pharma companies helps Torrent fill white spaces in areas like nephrology and gives an entry into the CDMO segment
Scrip collates data on the global manufacturing network of leading Indian drug makers, the markets serviced and production hubs for active pharmaceutical ingredients. Will ongoing geopolitical tensions and policy shifts have a bearing on some of these down the line?
GSK tells Scrip about timelines for data expected from two Phase II trials for its Bharat Biotech-partnered shigella vaccine candidate, which puts it ahead of Limmatech/Valneva. Meanwhile, a global-first malaria vaccine, also partnered with Bharat, sees an over 50% price cut
